ProKidney Corp.
PROKProKidney is a late-clinical-stage biotechnology company focused on developing autologous cell therapies to preserve kidney function in patients with advanced chronic kidney disease (CKD).
Table of contents
Earnings
Next report
Aug 11, 2026 (In 4 weeks)Competitors
By market cap
By revenue growth
Profile
ProKidney is a late-clinical-stage biotechnology company focused on developing autologous cell therapies to preserve kidney function in patients with advanced chronic kidney disease (CKD). Their lead product candidate, rilparencel, utilizes a patient's own kidney cells to stabilize or improve kidney function, potentially delaying or preventing the need for dialysis or transplantation.
ProKidney is a pioneer in autologous cell therapy for CKD, with the only cell therapy currently in Phase 3 clinical trials for advanced CKD and type 2 diabetes.
Questions, answered.
- What is ProKidney Corp.'s market cap?
- ProKidney Corp. (PROK) has a market capitalization of $369.4M and trades on NASDAQ.
- Who are ProKidney Corp.'s competitors?
- ProKidney Corp.'s key competitors include Janssen Pharmaceuticals, Inc., AstraZeneca plc, Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
- Who does ProKidney Corp. partner with?
- ProKidney Corp.'s notable partners include Janssen Pharmaceuticals, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, and others.
- What subsidiaries does ProKidney Corp. have?
- ProKidney Corp.'s subsidiaries include ProKidney Holdings, LLC, ProKidney IPCo, LLC.
- Where is ProKidney Corp. headquartered?
- ProKidney Corp. is headquartered in United States of America and employs approximately 163 people. It has been publicly traded since 2022.